Halloran is a nephrologist – researcher with a focus on organ transplantation and organ diseases, at both the clinical and basic levels. He received his MD and nephrology training from the University of Toronto and his PhD from the University of London. He served on the faculty of the University of Toronto before joining the University of Alberta. His research interests include the mechanisms of organ transplant rejection and injury, and the development of treatments to improve outcomes in transplantation and primary organ diseases. He has studied T cell-mediated rejection and described antibody-mediated kidney rejection, now recognized
as the leading cause of late kidney transplant loss (1;2). Dr.
Halloran is an author of over 300 peer
Halloran developed the Alberta Transplant Applied Genomics Centre (ATAGC), the world’s leading center
for molecular studies of organ transplants and organ diseases (http://atagc.med.ualberta.ca/
). He has recently developed the Molecular Microscope® Diagnostic System (MMDx
), a system for reading organ transplant biopsies using microarrays that is
now being licensed commercially (6).
He was the founding Editor-in-Chief of the world’s leading transplantation journal, the American Journal of Transplantation from 2000 to 2010. He is also the Chairman of the Board of Trustees of the Roche Organ Transplant Research Foundation, a Swiss-based charity. He is an Officer of the Order of Canada, a Fellow of the Royal Society of Canada, and an elected member of the American Society of Clinical Investigation. He is the first recipient of the Paul Terasaki Award from the American Society for Histocompatibility and Immunogenetics. In 2016 he was awarded the medical research Prix Galien for Canada and was named honorary professor at the University of Paris.